A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers

Takashi Eto, Yuji Karasuyama, Verónica González, Ana Del Campo García, Takashi Eto, Yuji Karasuyama, Verónica González, Ana Del Campo García

Abstract

Purpose: MB02 is a biosimilar to bevacizumab that has demonstrated similar physicochemical and functional properties in in vitro studies to the reference bevacizumab (Avastin®). This study aims to assess the pharmacokinetic (PK) similarity of MB02 to the reference bevacizumab in Japanese population.

Methods: This double-blind, randomized, parallel-group, single-dose PK study, was performed in healthy Japanese male volunteers. Subjects were equally randomized (1:1) to receive a single (3 mg/kg) IV dose of MB02 or reference bevacizumab. PK assessments were done up to 70 days post-dose. Non-compartmental parameters were calculated. PK similarity was determined using predefined equivalence range (0.80-1.25) for the area under the serum concentration-time curve from time 0 extrapolated to infinity (AUC0-∞). Immunogenicity samples were taken pre-dose and up to day 70. Safety was assessed throughout the study.

Results: In total, 48 subjects (24 in each treatment group) were dosed. Consequently to the observed similar PK profile, the 90% confidence interval for the geometric means ratio for the primary PK endpoint, AUC0-∞, was within the predefined equivalence range (0.981-1.11). Forty-seven treatment-emergent adverse events (TEAEs) were reported in 20 subjects (41.7%) with comparable incidence among MB02 and reference bevacizumab groups (22 and 25, respectively), none of them was severe or serious. Anti-drug antibodies incidence was low and similar between treatment groups.

Conclusions: Pharmacokinetic similarity of MB02 to reference bevacizumab was evidenced in Japanese healthy subjects, with comparable safety and immunogenicity profile between treatments. This study supports the biosimilarity of MB02 to reference bevacizumab in Japanese population. ClinicalTrials.gov identifier: NCT04238650.

Keywords: Bevacizumab; Biosimilars; Japanese; MB02; Pharmacokinetics; Safety.

Conflict of interest statement

VG and ADCG are employees of mAbxience Research SL. The other authors declare that they have no conflict of interest.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Study participants flow
Fig. 2
Fig. 2
Arithmetic mean serum concentration–time profiles of bevacizumab following single IV doses of MB02 and reference bevacizumab to healthy Japanese male subjects (up to 14 days and across All days). Pharmacokinetic population [Linear (A) and Semi-Logarithmic (B) Scale]

References

    1. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9–22. doi: 10.1096/fasebj.13.1.9.
    1. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34(12):1785–1788. doi: 10.1248/bpb.34.1785.
    1. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi: 10.1016/j.ctrv.2020.102017.
    1. Cherny NI, Sullivan R, Torode J, Saar M, Eniu A. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Ann Oncol. 2017;28(11):2633–2647. doi: 10.1093/annonc/mdx521.
    1. Matsumoto T, Tsuchiya T, Hirano T, et al. Changes in the penetration rate of biosimilar infliximab within japan using a Japanese claims database. Clin Econ Outcomes Res. 2021;13:145–153. doi: 10.2147/CEOR.S293698.
    1. European Medicines Agency (EMA) (2020) Guideline on similar biological medicinal product (Rev 1). . Accessed 17 Dec 2020
    1. EMA Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: clinical and nonclinical issues. (2015) CHMP/BMWP/42832/2005 Rev1 of 18 December 2014. . Accessed 17 Dec 2020
    1. United States Federal Drug Administration (US FDA) (2020) Scientific considerations in demonstrating biosimilarity to a reference product. . Accessed 17 Dec 2020
    1. Ministry of Health, Labour and Welfare (2009) Guideline for the quality, safety and efficacy assurance of follow-on biologics. PFSB/ELD notification No. 0304007. Provisional translation (as of April 19, 2013). Accessed 17 Dec 2020
    1. Ministry of Health, Labour and Welfare (2015) Questions and answers (Q&A) regarding the guideline for the quality, safety, and efficacy assurance of follow-on biologics (Biosimilars). Provisional translation (Dec 15, 2015). Accessed 17 Dec 2020
    1. Ministry of Health, Labour and Welfare (2020) Guideline for the quality, safety and efficacy assurance of follow-on biologics. PFSB/ELD notification No. 204–1 provisional translation (4 Feb 2020). (in Japanese) Accessed 23 Mar 2021
    1. Keene ON. The log transformation is special. Stat Med. 1995;14(8):811–819. doi: 10.1002/sim.4780140810.
    1. Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77:839–846. doi: 10.1007/s00280-016-3001-2.
    1. Hettema W, Wynne C, Lang B, et al. A randomized, single-blind, phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opin Investig Drugs. 2017;26(8):889–896. doi: 10.1080/13543784.2017.1347635.
    1. Tajima N, Martinez A, Kobayashi F, He L, Dewland P. A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers. Pharmacol Res Perspect. 2017;5(2):e00286. doi: 10.1002/prp2.286.
    1. Markus R, Chow V, Pan Z, Hanes V. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2017;80(4):755–763. doi: 10.1007/s00280-017-3416-4.
    1. Genentech Inc (2016) Avastin® (bevacizumab) prescribing information. . Accessed 17 Dec 2020
    1. Hanes V, Chow V, Pan Z, Markus R. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemother Pharmacol. 2018;82:899–905. doi: 10.1007/s00280-018-3695-4.
    1. Arato T. Japanese regulation of biosimilar products: past experience and current challenges. Br J Clin Pharmacol. 2016;82:30–40. doi: 10.1111/bcp.12931.
    1. Nagasaki M, Ando Y. Clinical development and trial design of biosimilar products: a Japanese perspective. J Biopharm Stat. 2014;24:1165–1172. doi: 10.1080/10543406.2014.941983.
    1. European Medicines Agency (EMA) (2020) Avastin®: EPAR-product information. annex I- summary of product characteristics. . Accessed 17 Dec 2020
    1. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779–786. doi: 10.1007/s00280-007-0664-8.
    1. Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016;78:341–351. doi: 10.1007/s00280-016-3079-6.
    1. Trukhin D, Poddubskaya E, Andric Z et al (2021) Efficacy, safety and immunogenicity of MB02 (Bevacizumab Biosimilar) versus reference Bevacizumab in advanced non-small cell lung cancer: a randomized, double-blind, phase III study (STELLA). BioDrugs. 10.1007/s40259-021-00483-w

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit